Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Quipazine is an agonist of the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2B, and 5-HT2C.1 It induces calcium accumulation in CHO-K1 cells expressing 5-HT2A, 5-HT2B, or 5-HT2C (EC50s = 309.03, 177.83, and 338.84 nM, respectively, for the human receptors). Quipazine also binds to the 5-HT3 receptor (Ki = 2.1 nM).2 It decreases food intake in rats when administered at doses of 2.5, 5, or 10 mg/kg.3 Quipazine (0.3 mg/kg per day), in combination with 8-hydroxy DPAT (Item No. 22608), electrode stimulation of dorsal and lumbar spine regions, and locomotor training, restores spinal circuitry function, improves gait regularity, and increases interlimb coordination and limb weight-bearing in a rat model of hindlimb paralysis induced by spinal cord transection.4
WARNING This product is not for human or veterinary use.
1. Functional characterization of agonists at recombinant human 5-
2. Identification of serotonin 5-
3. Decrease of food intake by quipazine in the rat: Relation to serotoninergic receptor stimulation. J. Pharm. Pharmacol. 29(1), 53-54 (1977).
4. Transformation of nonfunctional spinal circuits into functional states after the loss of brain input. Nat. Neurosci. 12(10), 1333-1342 (2009).